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Abstract13 
 3 
Glioblastomas are highly aggressive brain tumors with a particularly poor prognosis.1 
Potentially related is glucose transporter-1 (GLUT1/SLC2A1), a uniporter expressed by various 2 
carcinomas that may be involved in malignant neoplasm glycometabolism, including glioblastomas.3 
GLUT1 is essential to the central nervous system depend on glucose for glycometabolism. To clarify the4 
exact role of GLUT1 in glioblastoma, we assessed the expression and localization of GLUT1 in patient 5 
samples by immunohistochemistry and in situ RNA hybridization. This revealed that GLUT1 was mainly 6 
expressed on perivascular and pseudopalisade tumor cell membranes. All samples expressed GLUT1 to 7 
some degree, with 30.8% showing stronger staining. Based on these data, samples were divided into high 8 
and low expression groups, although SLC2A1 mRNA expression was also higher in the high GLUT1 9 
expression group. Kaplan-Meier survival curves revealed that high GLUT1 expression associated with10 
lower overall survival (log-rank test, p = 0.001) and worse patient prognoses (p = 0.001). Finally, MIB-111 
staining was stronger in high GLUT1 expression samples (p = 0.0004), suggesting a link with 12 
proliferation. We therefore hypothesize that GLUT1 expression in glioblastomas may enhance glycolysis,13 
affecting patient prognosis. Examination of GLUT1 in patients with glioblastomas may provide a new 14 
prognostic tool to improve outcome.15 
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Introduction1 
The glucose transporter (GLUT) protein family contains various important molecules that use2 
glucose diffusion gradients (and those of other sugars) for transport across the plasma membrane. They 3 
exhibit various substrate specificities, kinetic properties, and tissue expression profiles, depending on 4 
their role (1). The GLUT protein family belongs to a larger facilitator superfamily of membrane 5 
transporters (2), with 13 related members of the SLC2A (GLUT) protein family identified in humans (3).6 
Structurally, these molecules are divided into three classes; GLUT1–4 (class 1); GLUT5, 7, 9, and 11 7 
(class 2); and GLUT6, 8, 10, and 12 (class 3) (2). In the central nervous system, GLUT1 plays a critical 8 
role in cerebral glucose uptake and is the major GLUT isoform expressed in brain endothelial cells and 9 
brain astrocytes. It has been suggested that GLUT1 supplies glycolytically- derived lactate to neurons as a 10 
major fuel source (4, 5). The protein is a 492-amino-acid uniporter that is expressed by endothelial cells 11 
of the blood brain barrier (BBB). In humans, it is encoded by the SLC2A1 gene (6) and the GLUT112 
protein possesses 12 transmembrane segments, a single site of N-linked glycosylation, a relatively large, 13 
central, cytoplasmic linker domain, and also exhibits a topology where both the N and C terminals are 14 
positioned in the cytoplasm (6). In 1996, Younes et al. reported that GLUT1 expression in colorectal 15 
carcinomas associated with high incidence rates of lymph node metastasis (7). Subsequently, numerous 16 
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studies have reported contradictory evidence of the relationships between GLUT1 expression and 1 
prognosis in solid human tumors (8–14). Of note is a comprehensive meta-analysis of 2948 patients 2 
across 26 different studies that indicated that GLUT1 expression was a promising biomarker for 3 
prognosis, consistently showing an association with overall survival at three and five years (15). Among 4 
the tumor types evaluated, higher expression of GLUT1 in tumor tissues was also linked to worse overall 5 
survival at three and five years in oral squamous cell carcinomas and breast cancers (15). The expression 6 
of GLUT1 in astrocytomas and glioblastomas has also been reported to correlate with hypoxia-inducible 7 
factor-1 (HIF-1) in pseudopalisades, suggesting a link to hypoxia (16–20). However, the exact role of 8 
GLUT1 in tumorigenesis remains to be elucidated in highly aggressive glioblastomas. To address this, the9 
present study analyzed the expression of GLUT1 in IDH wildtype, WHO grade IV glioblastomas and any 10 
correlation with patient prognosis.11 
Materials and Methods12 
Patient Samples13 
Surgically collected tissue samples from 52 patients with glioblastomas were analyzed in the 14 
present study. All tumor specimens were retrieved from the archives of Kurume University Hospital,15 
Kurume, Japan between 2010 and 2016. The study was performed in accordance with the principles of 16 
 6 
the Helsinki Declaration and was approved by the institutional ethics committee. All specimens were 1 
histologically diagnosed as IDH-wildtype glioblastoma using World Health Organization (WHO) criteria 2 
(21). Multivariate survival analysis was used to assess the significance of various prognostic factors,3 
including complete resection, radiotherapy, age (>18 y), Karnofsky performance status (KPS) scores, and 4 
the expression of GLUT1. 5 
Immunohistochemistry6 
Tissue samples were fixed in 10% buffered formalin, embedded in paraffin, and processed 7 
using conventional histological and immunohistochemical methods. Sections 5- m thick were stained 8 
with hematoxylin and eosin (HE) for histological evaluation. The remaining unstained serial sections 9 
were used for immunohistochemistry analysis following heat-induced antigen retrieval. These were10 
stained with the appropriate antibodies and expression was evaluated with immunoperoxidase 11 
(ChemMate ENVISION kit/HRP[DAB]; DakoCytomation, Carpinteria, CA) using a Dako Autostainer 12 
Universal Staining System (DakoCytomation). The primary antibodies used were anti-GLUT1 (1:3200; 13 
Abcam, Cambridge, UK), anti-endoglin (CD105; 1:50; Novocastra, Newcastle, UK), and anti-Ki-67 14 
(MIB-1; 1:100; Immunotech, Marseille, France). MIB-1 labeling indices were determined as the 15 
percentage of the nuclear area stained in areas of maximal labeling. GLUT1 expression in glioblastomas16 
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was evaluated as both staining intensity and the number of stained cells by two observers in independent 1 
examinations. Samples that varied significantly between the two observers were re-evaluated to arrive at 2 
a consensus. 3 
Fluorescence immunohistochemical staining4 
5 
in tumor tissues was performed. Double staining was performed in a glioblastoma sample with 6 
anti-GLUT1 (1:100, Thermo, UK), anti-Ki67 (1:100, Dako, Denmark), and anti-CD34 (1:100, Leica, UK) 7 
antibodies followed by addition of anti-rabbit IgG-Texas Red (TR; sc-2780, Santa Cruz Biotechnology, 8 
Santa Cruz, CA, USA) and anti-mouse IgG-Alexa488 (Life Technologies, Carlsbad, CA, USA).9 
Assessment of staining co-localization was performed using the OPAL 7-color fIHC Kit (Perkin Elmer, 10 
Watham, MA, USA) according to the manufacturer’s protocols. Fluorescence was measured using a 11 
fluorescent microscope (BX51FL, Olympus, Tokyo, Japan) and a charged-coupled device camera (DP71, 12 
Olympus, Tokyo, Japan).13 
DNA Isolation and Mutation Analysis14 
The mutational statuses of IDH1 and IDH2 were determined by Sanger sequencing. Briefly, 15 
genomic DNA was isolated from the relevant formalin-fixed paraffin-embedded (FFPE) tissue blocks by 16 
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cutting 10-μm thick sections, followed by extraction using a QIAamp DNA Micro Kit (Qiagen, Hilden, 1 
Germany). IDH1 exon 4 and IDH2 exon 4 were amplified by polymerase chain reaction (PCR) with the 2 
indicated primers (Table 1). The amplifying conditions for IDH1 and IDH2 were both an initial 3 
denaturing step of 95 °C for 10 min, followed by 40 cycles of denaturation at 95 °C for 30 s, an annealing4 
step at 60 °C for 30 s, and then extension at 72 °C for 30 s, with a final extension at 72 °C for 10 min. 5 
PCR products were separated on 2% agarose gels by electrophoresis, excised, and then sequenced on an 6 
ABI PRISM 310 Genetic Analyzer (Life Technologies, Gaithersburg, MD). Analyses of sequence data 7 
were performed using GENETYX software Ver. 10 (GENETYX, Tokyo, Japan) and a reference sequence 8 
complementary to each gene. 9 
RNAscope10 
SLC2A1 (GLUT1) mRNA in situ hybridization (ISH) was performed using an RNAscope 2.5 11 
HD Assay Kit-BROWN (ACD, Newark, CA), according to the manufacturer’s protocols. Tissue sections12 
2.5- m thick were deparaffinized in xylene and dehydrated through an ethanol series. The sections were 13 
then incubated in citrate buffer (10 nmol/L, pH 6.0) and maintained at 100 °C to 103 °C for 15 min using 14 
a hot plate. They were then rinsed in deionized water and immediately treated with 10 g/mL protease 15 
(Sigma-Aldrich, St. Louis, MO) at 40 °C for 30 min in a HybEZ hybridization oven (Advanced Cell 16 
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Diagnostics, Hayward, CA). Hybridization with target probes, preamplifier, amplifier, label probes, and 1 
chromogenic detection were performed as previously described for cultured cells. RNAscope scores and 2 
the heterogeneity of SLC2A1 mRNA signals were estimated using the manufacturer’s recommended 3 
protocols and a semiquantitative scoring system. The staining scores were 0; no staining or less than 1 dot 4 
to every 10 dots, staining score 1; 1–3 dots/cell, staining score 2; 4–10 dots/cell or very few dot clusters, 5 
staining score 3; >10 dots/cell and less than 10% positive cells with clusters, staining score 4; >10 6 
dots/cell and 10% positive cells with clusters. The evaluation was performed by three observers (SK, YS,7 
and KY) across independent examinations.8 
Cell culture9 
Human glioma cell lines T98, U87, and U251, were obtained from American Type Culture 10 
Collection (ATCC) in 2009. Authentication of the cell lines was unnecessary because cells were expanded 11 
by culturing them for less than two passages and stored at °C. Low-passage cells were used for 12 
experiments within 6 months after resuscitation. They were maintained in Dulbecco’s modified Eagle 13 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 14 
g/mL streptomycin. 15 
Cell viability and cell proliferation16 
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Cell proliferation was evaluated in triplicates by a colorimetric WST-1 assay (Roche, 1 
Germany) according to the manufacturer’s protocol. Practically, 1,000 cells of each population were 2 
seeded in 96-well plastic plates in 200 L of culture medium supplemented with 0.1% FBS. The plates3 
were incubated for 4 h at 37°C. Twenty microliters of WST-1 (10% of total volume) was added to the 4 
cells, and the cells were incubated. The plate was read using DS2® (Dynex, USA) by measuring the 5 
absorbance of the dye at 450 nm, with 600nm set as the reference wavelength. Averages of the 6 
absorbance values were calculated and plotted. The cells were treated with various concentrations of 7 
WZB-117 (Sigma-Aldrich, Germany), a specific GLUT-1 inhibitor.8 
Statistical Analysis9 
To reveal any correlation between the expression of GLUT1 in glioblastomas and patient 10 
prognoses, statistical analysis among the relevant groups was performed using JMP13 (SAS Institute Inc., 11 
Cary, NC). Survival rates were computed using Kaplan-Meier curves. Patients were excluded if they were 12 
lost to follow-up at the time of analysis. Cox proportional hazards regression models were used for 13 
multivariate analyses of overall survival. In addition, Kendal tau rank correlation tests were performed 14 
between GLUT1 expression, Ki-67 labeling indices, and the number of CD105 (endoglin) positive 15 
vessels in glioblastomas. Statistical significance was set at a threshold of p < 0.05.16 
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Gene expression database1 
Information regarding SLC2A1 alterations and patient’s survival time in 2 
glioblastomas was downloaded from the Cancer Genome Atlas (TCGA) Database, an open access 3 
database that is publicly available at http:///www.cbioportal.org [38, 39]. Six hundred and four 4 
glioblastoma cases (TCGA, Provisional) were selected. These cases were divided into two groups: 5 
SLC2A1 mRNA up-regulated or not altered. Gene altered cases were defined as that expression level of 6 
SLC2A was observed greater than standard-deviation from the mean. The proportion of up-regulated 7 
cases was calculated and overall survival and progression-free survival were estimated by Kaplan-Meier 8 
analysis. Furthermore, co-expression genes with SLC2A1 in glioblastomas were investigated by 9 
calculating Spearman’s correlation coefficients. We selected VEGF as the neoangiogenetic marker, CD4410 
as the mesenchymal marker, PDGFR as proneural marker, TGF- as the epithelial mesenchymal 11 
12 
Result13 
Clinical Data14 
A summary of the clinical information for the 52 patients with glioblastomas is shown in 15 
Table 2. The median age at diagnosis was 65.9 (33–86) years and 18 cases (34.6%) were female, 34 cases 16 
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(65.4%) male. The median KPS at diagnosis was 74.0 (30–90) years. Tumors were localized to the frontal 1 
lobe in 21 cases, the temporal lobe in 18 cases, the parietal lobe in nine cases, and in other regions for the 2 
remaining four cases. All patients received surgical treatment, followed by chemoradiotherapy with 3 
temozolomide.4 
Expression of GLUT15 
Our study showed that GLUT1 was expressed on tumor cell membranes in all 52 cases,6 
supporting previous reports (13, 19). The intensity of staining could be divided into three categories, mild 7 
(grade 1; Fig. 1B), moderate (grade 2; Fig. 1C), or strong (grade 3; Fig. 1D). Six high power fields in 8 
each tissue samples were randomly selected and used to calculate the ratio of grade 2 to grade 39 
assessments across the tumor sample. We defined a ratio of more than 20% between grade 2 and 3 as the10 
high GLUT1 expression group, whereas ratios less than 19% were defined as a low expression group. 11 
Using these criteria, high expression of GLUT1 was detected in 16 cases and low expression was detected12 
in 36 cases. Using an RNAscope system, SLC2A1 mRNA was detected in glioblastoma tumor cells as13 
either brown distinct points or clustered patterns (Fig. 2). A semi-quantitative four-level staining score 14 
was established for the RNAscope data. Samples defined as grades 3 or 4 (high expression) in the 15 
RNAscope study were the same as the GLUT1 high expression samples. In contrast, RNAscope staining 16 
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scores of grades 1 or 2 (low expression) were found in the GLUT1 low expression group. These data 1 
confirm that both GLUT1 and SLC2A1 mRNA expression differ in glioblastomas, and that there is an 2 
association between protein and transcript.3 
Localization of GLUT14 
We next assessed the localization of GLUT1-positive cells in tissues, revealing that GLUT15 
cells were located at the perivascular pseudopalisading cells and in tumor cells at the boundary between 6 
tumors and normal brain tissue (Fig. 3). Especually, GLUT1-positive cells were more commonly found at 7 
the perivascular region, in addition to pseudopalisades and tumor boundaries (Fig. 3D). This suggests that 8 
GLUT1 expression associates with these migratory and hypoxic areas, indicating a link with 9 
glycometabolism. To show localized GLUT1 expression, double immunofluorescence was performed. 10 
Glioblastoma cells expressing GLUT1 were observed around CD34-positive blood vessels (Figure 5A).11 
were co-expressed in pseudopalisading necrosis (Figure 5B). These 12 
findings supported the specific localization of GLUT1 expression in hypoxic area of glioblastomas.13 
Association Between GLUT1 Expression, Angiogenesis, and Proliferation14 
Next, CD105 staining was used as a marker to distinguish between normal vessels and 15 
malignant intratumoral neovascularization to assess any correlation between high GLUT1 expression and 16 
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angiogenesis. Averages of CD105-stained cell counts from three areas were recorded as CD105 1 
intratumoral vessel density to compare the degree of angiogenesis. This showed that GLUT1 in the high 2 
expression group more frequently associated with CD105 positive vessels relative to the low GLUT1 3 
expression group (Fig. 4A). The number of CD105 positive vessels positively correlated with the number 4 
of GLUT1-positive cells in the high expression tumors (correlation coefficient: 0.61). We also 5 
measured if there was any correlation between the expression of GLUT1 and tumor cell proliferation in 6 
glioblastomas using MIB-1 labeling indices. MIB-1 staining was immunohistochemically evaluated 7 
across continuous sections, revealing that the MIB-1 labeling indices in the high GLUT1 expression 8 
group were higher than that in the low expression group (Wilcoxon test: p < 0.001; Fig. 4B). Furthermore, 9 
double fluorescent immunostainings for GLUT1 and MIB-1 suggested that tumor cells with high 10 
proliferative potency expressed GLUT1 (Figure 5C). Together, these data indicate a link between GLUT1 11 
angiogenesis and glioblastoma cell proliferation.12 
Cell proliferation and viability13 
GLUT1 expression of U87, U251, and T98 cells was confirmed by western blot analysis (data 14 
not shown). The viability of T98 and U87 with WZB-117 decreased in a concentration-dependent manner 15 
(Figure 6A, 6B), whereas -117 (Figure 6C).16 
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Association Between GLUT1 Expression and Patient Survival1 
Finally, Kaplan-Meier survival curve analysis indicated that the high GLUT1 expression 2 
group had lower overall survival rates than the low expression group (log-rank test: p = 0.001; Fig. 6D).3 
There were no differences between progression free survival rates in the high and low expression groups4 
(data not shown). A further multivariate analysis showed that GLUT1 was an independent predictor for 5 
poor prognosis when compared to already known prognostic factors, such as age or KPS (Table 3; hazard 6 
ratio 5.59, 95% confident interval 2.22–14.4, p = 0.0003). This suggests that GLUT1 is a novel7 
independent predictor for glioblastoma outcome.8 
Gene expression database9 
To validate the result of the present study, data from TCGA database regarding 10 
GLUT1 in glioblastomas was analyzed (refer to Supplemental data). Two hundred and forty nine cases 11 
(42%) showed up-regulated SLC2A1 in 591 glioblastomas from TCGA database. The overall survival of 12 
up-regulated cases tended to be shorter than the not altered cases (Log-rank test; p=0.375, Supplemental 13 
figure 1A), and the progression free survival of up-regulated cases was significantly shorter than the not 14 
altered cases (Log-rank test; p=0.01, Supplemental figure 1B). SLC2A1 correlated with VEGF 15 
(Spearman’s correlation coefficient 0.63, Supplemental figure 2A, TGF- (Spearman’s correlation 16 
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coefficient 0.35, Supplemental figure 2B) and HIF1 (Spearman’s correlation coefficient 0.33, 1 
Supplemental figure 2C). CD44 and PDGFR did not show significant correlation with SLC2A1. These 2 
data from genome-wide analyses implied that GLUT1 was related with angiogenesis and hypoxia in 3 
glioblastoma as a whole tumor.4 
Discussion5 
Glioblastomas are extremely aggressive tumors of the central nervous system that have a 6 
particularly poor outcome. Previously, it has been shown that glioblastomas are in a relatively hypoxic7 
state with a degree of undernutrition due to their high proliferative potency and invasive capacity (22, 23).8 
This assessment has been supported by several studies that have reported hypoxic environments in 9 
glioblastomas (16–20, 24). Using these data and a reverse interpretation of the Pasteur effect, it can be 10 
inferred that the energy metabolism of glioblastomas under hypoxia would depend on the glycolytic 11 
system (25). Angiogenesis elicited by such hypoxia would result in an aerobic environment and the12 
glycolytic system of these tumor cells would be enhanced by the Warburg effect (25). However,13 
irrespective of whether tumor cells are under an aerobic or anaerobic condition, tumor cells require an 14 
enormous amount of glucose to meet their energy requirements. Our study indicates that glioblastoma15 
cells up-regulate the GLUT1 transporter to promote glucose uptake in order to meet these high 16 
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requirements. The present study also suggests a correlation between GLUT1 expression and MIB-11 
labeling indices, suggesting a link between cell proliferation and the transporter. GLUT1 expression was 2 
observed in high proliferative glioblastoma cells positive for MIB-1 (Figure 5C).3 
During our study, GLUT1 expression was evaluated in IDH wild-type glioblastomas using4 
immunohistochemistry (to evaluate protein expression) and RNAscope in situ hybridization (to evaluate 5 
transcript expression). RNAscope allows single-molecule visualization in individual cells to be achieved 6 
through the use of a novel probe design strategy and a hybridization-based signal amplification system 7 
that suppresses background noise (26). Previously, a number of studies have reported a link between 8 
certain mRNAs and cancer. Among them, Wang et al reported the efficacy of the RNAscope technique 9 
for examining invasive breast carcinomas that compared it to real-time quantitative PCR (qPCR) and10 
other US Food and Drug Administration (FDA)-approved methods, including fluorescence 11 
in situ hybridization (FISH) (27). Both RNAscope and qPCR data matched the FISH analysis in 97.3% of 12 
cases, showing that RNAscope is as accurate as qPCR and FISH (27). Importantly, the RNAscope13 
approach can be used with archived FFPE tissues on glass slides and can be visualized either under a14 
standard bright-field microscope (with chromogenic labels) or an epifluorescent microscope. A clear 15 
advantages of RNAscope is therefore its ability to visualize localized mRNA expression in samples. In 16 
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the current study, GLUT1 protein expression was found to localize to glioblastoma cells and this was 1 
supported by our RNAscope analysis of SLC2A1 expression (Fig. 4). Highly stained samples in the2 
GLUT1 high expression group had similarly high SLC2A1 scores. Conversely, the GLUT1 low 3 
expression group had lower SLC2A1 scores.4 
Our study also revealed that GLUT1 expression was mainly localized to perivascular tumor 5 
cells. There was also a positive correlation between GLUT1 expression and neoangiogenesis highlighted6 
by CD105 (endoglin) staining. CD105 is a 180 kDa integral membrane glycoprotein that is an accessory 7 
component of the transforming growth factor-beta (TGF- receptor complex. Applying analysis of 8 
CD105 expression to distinguish between normal vessels and malignant neovascularization has 9 
previously been reported, supporting our interpretation (28–30). The protein is predominantly expressed 10 
on cellular lineages within the vascular system, although it is more highly expressed by proliferating 11 
endothelial cells that participate in tumor angiogenesis. This pattern may emerge due to relatively lower12 
expression in the vascular endothelium of normal tissues (31, 32). Markowski et al. also reported that the 13 
expression levels of HIF-1 , SLC2A1 (GLUT1), and CD105 were higher in a group of patients with 14 
bladder cancer when compared to healthy subjects (30). The validation of the positive correlation of 15 
SLC2A1 and VEGF from TCGA database and GLUT1 expression around CD34 positive vessels 16 
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suggested GLUT1 was related with tumor neoangiogenesis. Combined, these data indicate that there is a1 
link between GLUT1 and endoglin expression, suggesting that the glycolytic system that emerges during 2 
glioblastoma development is accelerated by neoangiogenesis.3 
In addition, our examination of the localization of GLUT1 within tumor tissues has revealed 4 
an association with pseudopalisade formation and microvascular proliferation, both pathological features5 
of glioblastomas. The generation of pseudopalisades, hypercellular zones surrounding necrotic tissue, 6 
often results from the migration of glioma cells outwards from hypoxic areas due to vascular occlusion 7 
(33). Epithelial-mesenchymal transition (EMT) is the process by which epithelial cells lose cell polarity 8 
and adhesiveness and is one of the main mechanisms that exacerbates tumor migration in glioblastomas 9 
(31). The zinc finger E-box-binding homeobox (ZEB) proteins, ZEB1 and smad1-interacting protein-110 
(also known as ZEB2), are another family of noteworthy transcription factor that are responsible for the 11 
mediation of epithelial-mesenchymal transition in numerous types of cancer including glioma (41). Chem 12 
et al. detected the expression of ZEB1 and ZEB2 in 91 cases of GBM with immunohistochemistry (42).13 
The percentages of ZEB1 high expression and ZEB2 high expression were 31.9% (29/91) and 41.9% 14 
(36/91), respectively. They revealed that high expression of ZEB2 was significantly associated with lower 15 
survival rate of GBM patients (P=0.001). Justin V et al. revealed hypoxia-induced mesenchymal shift in 16 
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GBM primary material by showing co-localization of GLUT1, ZEB1 and the mesenchymal marker 1 
YKL40 in hypoxic regions of the tumor (43). These results suggested that GLUT1 may exist on 2 
downstream of ZEB1 pathway, further examination is needed in order to clarify the relationship GLUT1 3 
and ZEB1. In past reports, GLUT1 has been found to associate with lymph node metastasis and is also 4 
highly expressed by breast cancer cells (10, 35). These studies also reported that GLUT1 expression 5 
contributed to increased tumor viability by promoting glycolysis. The results showing that GLUT1 is 6 
expressed in both hypoxic and proliferative area suggested that glioblastoma cells increased their 7 
proliferative potency via hypoxic stress.8 
These studies, in combination with our own analysis showing GLUT1 localization at tumor9 
pseudopalisades, indicate a possible link to EMT. We therefore hypothesize that tumor malignancy in 10 
glioblastomas may be increased by GLUT1 through higher migration and invasiveness.11 
Finally, Kaplan-Meier survival curve analysis revealed that survival in the high GLUT112 
expression group was lower than the low expression group. Our multivariate analysis also showed that 13 
GLUT1 was an independent predictor for worse prognoses compared to already known prognostic factors,14 
including age and KPS. These data suggest that GLUT1 may act as an independent prognostic factor for 15 
glioblastoma due to an accelerated glycolytic system, likely through increased neoangiogenesis and the16 
 21 
Warburg effect. This would subsequently increase migration and invasiveness by promoting EMT.1 
Previously, Phadngam et al. reported that GLUT1 acts downstream of the PI3K-Akt pathway (25) and 2 
several studies have suggested a link between GLUT1, , and , although the exact details 3 
remain unclear. For example, Azzalin et al. reported that various inhibitors of GLUT/SLC2A enhance the 4 
activity of the chemotherapeutic agents bis-chloroethylnitrosourea (BCNU) and temozolomide against 5 
high-grade gliomas (36). Chen et al. also reported that specific blockade of GLUT1 using WZB117 6 
resensitizes breast cancer cells to adriamycin (37). In the present study, GLUT1 inhibition by WZB-1177 
decreased cell viability in cell lines. There is a great deal of scope for the therapeutic application of 8 
GLUT1 inhibitors against glioblastoma, although further experiments whether WZB-117 potentiate 9 
temozolomide and/or irradiation are required.10 
In conclusion, our study has revealed that GLUT1 is a biomarker and predictor for a worse 11 
prognostic outcome in patients with glioblastomas. This will assist the development and application of 12 
tools and treatment to better target vulnerable patients. However, recent advancements suggest that 13 
GLUT1 also has the potential to increase the efficacy of various anticancer agents. Therefore, our study14 
also contributes to this aim by elucidating several important characteristics of GLUT1 expression in 15 
glioblastomas.16 
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Figure 1.1 
Immunohistochemical intensity scores of GLUT1 staining in glioblastoma tumor cells. GLUT1 was 2 
found to be expressed at the tumor cell membranes in glioblastomas. The staining intensity scores were 3 
evaluated according to a four-grade system. (A) Negative cases showed no stain in tumor cells but 4 
positive in endothelium for GLUT1 (arrow), whereas tumor cell membranes were stained to varying 5 
degrees in positive cases and were divided into grade 1 (B, mild), grade 2 (C, moderate), and grade 3 (D, 6 
strong) staining.7 
Figure 2.8 
RNAscope in situ hybridization showing SLC2A1 (GLUT1) mRNA expression in high GLUT1 9 
expression samples. Tumor cells surrounding areas of necrosis or vessels that had (A) >10 dots/cell or (B)10 
10% positive cells with staining clusters (arrows) were assigned a score of 4. Tumor cells with (C) >10 11 
dots/cell or (D) less than 10% positive cells with clusters (arrows) were given a score of 3.12 
Figure 3.13 
Localization of GLUT1 expression in glioblastoma tumor cells. (A) Immunohistochemical staining 14 
showed that GLUT1 was expressed predominantly perivascular region. GLUT1 staining was found 15 
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around vessels (arrow) and formed a mottled pattern. (B) GLUT1 was also expressed in pseudopalisades 1 
of the tumor cell and (C) boundary area.2 
Figure 4.3 
(A) Number of cases in each localized expression of GLUT1. GLUT1-positive cells were most often 4 
observed at the perivascular regions. GLUT1 positive cells were also seen in pseudopalisades and at the 5 
boundaries between tumor and normal brain tissue. Cases are overlapping. (B) Correlation between 6 
GLUT1 expression and angiogenesis. Cases with high GLUT1 expression possessed more 7 
CD105-positive vessels (Wilcoxon test p < 0.001). In addition, high GLUT1 expression positively 8 
correlated with the number of CD105-positive vessels (correlation coefficient: 0.61). (C) Correlation 9 
between GLUT1 expression and proliferative capacity. The MIB-1 labeling indices of the high GLUT1 10 
expression group were higher than the low expression group (Wilcoxon test p < 0.001). In addition, high 11 
GLUT1 expression positively correlated with MIB-1 labeling indices (correlation coefficient: 0.51).12 
Figure 5.13 
Double immunofluorescent staining of GLUT1 and other markers. (A) GLUT1 staining (left) and CD34 14 
staining (center). Merged image (right) showed GLUT1 expression (red) around CD34 (green) positive 15 
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vessels. (B er). Merged image (right) showed GLUT1 1 
) positive cells. (C) GLUT1 staining (left) and Ki67 staining 2 
(center). Merged image (right) showed co-expression of GLUT1 and Ki67 (green) in tumor cells.3 
Figure 6. 4 
WST-1 cell proliferation assay and comparison of the Kaplan-Meier survival curves by GLUT1 5 
expression. (A-C) U87, U251, and T98 cells were incubated in WZB-117 of indicated concentrations for 6 
24 hours. Cell viability decreased in all tested cell lines in various manner. (D) Comparison of the 7 
Kaplan-Meier survival curves between the high and low GLUT1 expression groups showed that the high 8 
GLUT1 expression patient group had lower overall survival rates than the low expression group (log-rank 9 
test, p = 0.001).10 






1
Table 1. Primer design and PCR product
Gene Primer sequence Product
IDH1 Forward: 5’-GGTTGAGGAGTTCAAGTTGAAACAAAT-3’ 244bp
Reverse: 5’-CACATACAAGTTGGAAATTTCTGGGCC-3’
IDH2 Forward: 4’-GGGGTTCAAATTCTGGTTGAAAGATGG 289bp
Reverse: 5’-TAGGCGAGGAGCTCCAGTCGGG-3’
 
Table 2. Patients characteristics
Abbreviations; KPS, Karnofsky Performance Status
Characteristics n=52
Median age, years (range) 65.9 (33-86)
Sex, n (%)
Male 34 (65.4%)
Female 18 (34.6%)
Localization, n (%)
Frontal 21 (40.4%)
Temporal 18 (34.6%)
Parietal 9 (17.3%)
Others 4 (7.7%)
Median KPS at preoperation (range) 74.0 (30-90)
Surgical procedure, n (%)
Gross total resection 33 (63.4%)
Partial resection 19 (36.6%)
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Supplemental data
Material and Methods
Gene expression database
Information regarding SLC2A1 alterations and patient’s survival 
time in glioblastomas was downloaded from the Cancer Genome Atlas (TCGA) 
Database, an open access database that is publicly available at 
http:///www.cbioportal.org [38, 39]. Six hundred and four glioblastoma cases (TCGA, 
Provisional) were selected. Gene altered cases were defined as that expression level of 
SLC2A was observed greater than standard-deviation from the mean. These cases were 
divided into two groups: SLC2A1 mRNA up-regulated or not altered. The proportion of 
up-regulated cases was calculated and overall survival and progression-free survival
were estimated by Kaplan-Meier analysis. Furthermore, co-expression genes with 
SLC2A1 in glioblastomas were investigated by calculating Spearman’s correlation 
coefficients. We selected VEGF as the neoangiogenetic marker, NF1 as the
mesenchymal marker, TP53 as proneural marker, TGF- as the epithelial mesenchymal 
the hypoxic marker [40].
Result
Gene expression database
To validate the result of the present study, data from TCGA database 
regarding GLUT1 in glioblastomas was analyzed. Two hundred and forty nine cases 
(42%) showed up-regulated SLC2A1 in 591 glioblastomas from TCGA database. The 
overall survival of up-regulated cases tended to be shorter than the not altered cases
(Log-rank test; p=0.375, Supplemental figure 1A), and the progression free survival of 
up-regulated cases was significantly shorter than the not altered cases (Log-rank test;
p=0.01, Supplemental figure 1B). SLC2A1 correlated with VEGF (Spearman’s
correlation coefficient 0.63, Supplemental figure 2A, TGF- (Spearman’s correlation 
coefficient 0.35, Supplemental figure 2B) and HIF1 (Spearman’s correlation 
coefficient 0.33, Supplemental figure 2C). Other glioblastoma genes did not relate with 
SLC2A1. These data suggested that GLUT1 was related with angiogenesis and hypoxia 
in glioblastoma.
Supplemental Figure Legends
Supplemental Figure 1
Analysis of 591 glioblastomas from TCGA database. The overall survival of 
up-regulated cases was tended to be shorter than the not altered cases (Log-rank test; 
p=0.375, Supplemental figure 1A), and the progression free survival of up-regulated 
cases was significantly shorter than the not altered cases (Log-rank test; p=0.01, 
Supplemental figure 1B).
Supplemental Figure 2
Co-expression of genes and their correlation with SLC2A1 in glioblastomas from 
TCGA database. SLC2A1 expression was correlated with VEGF (Spearman’s
correlation coefficient 0.63, Supplemental figure 2A, TGF- (Spearman’s correlation 
coefficient 0.35, Supplemental figure 2B) and HIF1A (Spearman’s correlation 
coefficient 0.33, Supplemental figure 2C).


